Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD - J Clin Oncol 2003;21:679-689

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 410-411

Elsevier

Access to resources Recommend Favorite

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 - Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413, University of California-San Francisco, San Francisco, CA. J Clin Oncol 2003;21:1904-1911

By Smith J.A.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 482-482

Elsevier

Access to resources Recommend Favorite

Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma

By Satoh M.   Miyamura K.   Yamada M.   Ishidoya S.   Childs R.W.   Arai Y.  

Lancet Oncology, Vol. 5, Iss. 2, 2004-02 ,pp. : 125-126

Elsevier

Access to resources Recommend Favorite

Regression of metastatic renal-cell carcinoma after nonmyeloablative peripheral-blood stem-cell transplantation. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1652, USA.childsr@nih.gov

By Dreicer R.   Dreicer R.   Dreicer R.   Dreicer R.   Dreicer R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 3, 2001-05 ,pp. : 125-127

Elsevier

Access to resources Recommend Favorite

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufmann D, Moore M, Department of Medicine, University of Chicago, Chicago, IL - Urol Oncol 2002;7:153-157

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 413-413

Elsevier

Access to resources Recommend Favorite